Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1770 participants.
Also called NCT05192941
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,770 participants
- Sponsor
- Registry
-
NCT05192941
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Bulgaria, Czechia, Estonia, France, Germany, Latvia, Poland, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05192941. Randomized; quadruple masking; primary purpose treatment. Start 2022-04-08 (actual); primary completion 2024-06-11 (actual). Results posted on 2026-04-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
- Acronym
- V-DIFFERENCE
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Inclisiran Sodium
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05192941- Content hash
90a6763227fab968f7df273a5b5daac5c0c1161ffe049bc222ffc00b04c49200